Thermo Fisher Scientific has completed the acquisition of Solventum Corp’s purification and filtration business. The transaction, finalized in September 2025, was valued at approximately USD 4 billion. This acquisition integrates a diverse range of membrane-filter and separation solutions into the Thermo Fisher Scientific portfolio.
The acquired technologies from Solventum include advanced membrane solutions designed to support sterile filtration, protein concentration, and sample preparation. These products are utilized within bioprocessing and drug-development workflows. The integration of these assets is intended to strengthen Thermo Fisher Scientific’s market position within the laboratory-filtration sector, specifically addressing the increasing demand for high-performance separation products and single-use membranes driven by growth in pharmaceutical and biotechnology research.
As of the market close on November 16, 2026, Solventum Corp’s stock was priced at USD 86.06 on the New York Stock Exchange. The company maintains a market capitalization of USD 15,050,000,000 and a price-to-earnings ratio of 9.3. Over the previous 52 weeks, the stock has traded between a low of USD 62.38 on April 6, 2026, and a high of USD 94.16 on August 31, 2026.




